Fermenta Biotech has officially listed its shares on the National Stock Exchange, joining its existing listing on the BSE. The move follows recent regulatory approval for its plant-based Vitamin D3, as the company works to increase production for global nutrition markets.
Fermenta Biotech Ltd has expanded its market presence by listing its shares on the National Stock Exchange of India (NSE). The company, which has been listed on the BSE since 1977, now provides investors with access across both major Indian exchanges. This development marks a milestone in the company’s 75-year history as it seeks to strengthen its reach among a broader investor base.
Scaling Production for Nutrition Markets
The NSE listing coincides with a strategic push to scale the company's product offerings. In July 2026, Fermenta Biotech received approval from the Food Safety and Standards Authority of India (FSSAI) for its plant-source Vitamin D3, marketed under the brand Vitadee Green. Management has communicated plans to increase manufacturing capacity for this product within the next three months. This timing is critical as the company aims to meet rising demand in the health supplement, food fortification, and nutraceutical sectors.
Financial and Business Context
Fermenta Biotech maintains a concentrated revenue model, with Vitamin D3 sales accounting for more than 70% of its total income. For the financial year ended March 2026, the company recorded a total revenue of ₹551 crore. The company traces its corporate structure to a reverse merger completed between 2017 and 2018, which resulted in Fermenta becoming the primary listed entity after operating as a subsidiary of Duphar-Interfran Ltd. With operations spanning over 60 countries, the company continues to focus on specialized solutions, nutrition, and green chemistry applications.
Investors monitoring the company’s progress may focus on the execution of the planned production ramp-up for its newly approved plant-based Vitamin D3. The ability to successfully scale output and secure market share in both domestic and international segments will be a primary factor in evaluating the company's growth trajectory. Additionally, ongoing observation of the company’s revenue concentration in Vitamin D3 remains relevant, as the performance of this specific segment directly influences overall financial results.